Kenneth Shah, MD
Cardiovascular Disease · Henderson, NVNPI 1992755946
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 236 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 11.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,676 and has fallen 68.5% since, to $843 in 2025.
Across 236 payments — averaging $35.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$931
- Abbott$773
- Amgen$657
- Amarin Pharma, Inc.$514
- Novartis$457
- AstraZeneca$444
- plus $5K from 30 others
What the payments were for
- Food & beverage$8,28798%
- Education$1392%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 14 | $931 |
| Abbott | 11 | $773 |
| Amgen | 29 | $657 |
| Amarin Pharma, Inc. | 21 | $514 |
| Novartis | 17 | $457 |
| AstraZeneca | 17 | $444 |
| Actelion Pharmaceuticals US, Inc. | 7 | $436 |
| Arbor Pharmaceuticals, Inc. | 20 | $399 |
| Johnson & Johnson | 15 | $347 |
| Abiomed | 4 | $338 |
| Merck | 11 | $291 |
| Novo Nordisk | 11 | $284 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $221 |
| Bayer | 5 | $199 |
| Organogenesis Inc. | 1 | $197 |
| Cvrx, Inc. | 3 | $195 |
| Alnylam Pharmaceuticals Inc. | 3 | $170 |
| Akcea Therapeutics, Inc. | 2 | $164 |
| Sanofi-aventis U.S. LLC | 8 | $155 |
| Asahi Intecc USA, Inc. | 2 | $147 |
| Bridgebio Pharma, Inc. | 1 | $143 |
| Chiesi USA, Inc. | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 6 | $118 |
| Boston Scientific | 1 | $100 |
| Scpharmaceuticals Inc. | 1 | $96 |
| Impulse Dynamics (USA) Inc. | 2 | $94 |
| Pfizer | 5 | $92 |
| Kowa Pharmaceuticals America, Inc. | 3 | $76 |
| Nestle Healthcare Nutrition Inc. | 1 | $67 |
| Cleerly, Inc. | 1 | $50 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| AbbVie | 2 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| GSK | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Angiodynamics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$429
- UPTRAVI$350
- Impella$257
- OPSUMIT$239
- Vascepa$233
- CARDIOMEMS$231
- PuraPly$197
- Confirm Rx$152
- Barostim Neo System$146
- TEGSEDI$145
- Attruby$143
- AMVUTTRA$140
- 3F$137
- Kerendia$127
- KENGREAL 50MG/10ML L$125
- ENTRESTO$124
- ASAHI PTCA Guide Wire$123
- FARXIGA$123
- Reveal LINQ$118
- XARELTO$113
How this compares
$8,427 in reported general payments places this provider in the 70th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 77 | $79,611 |
| XareltoRivaroxaban | 41 | $48,605 |
| EntrestoSacubitril/Valsartan | 30 | $38,709 |
| JardianceEmpagliflozin | 21 | $19,722 |
| BrilintaTicagrelor | 24 | $17,663 |
| MultaqDronedarone Hcl | 11 | $13,918 |
| VascepaIcosapent Ethyl | 25 | $11,561 |
| Repatha SureclickEvolocumab | 14 | $7,778 |
| Icosapent Ethyl | 15 | $4,525 |
| Ranolazine ErRanolazine | 41 | $4,381 |
| Atorvastatin Calcium | 317 | $3,315 |
| Olmesartan Medoxomil | 136 | $3,111 |
| Nebivolol Hcl | 39 | $3,084 |
| Metoprolol Succinate | 158 | $2,207 |
| Bisoprolol Fumarate | 68 | $1,804 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $92 | $79,61177 claims |
| Johnson & JohnsonXarelto | $347 | $48,60541 claims |
| NovartisEntresto | $457 | $38,70930 claims |
| AstraZenecaBrilinta | $444 | $17,66324 claims |
| Sanofi-aventis U.S. LLCMultaq | $155 | $13,91811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Henderson
- Fareed SheikhHenderson$56K
- Tiffany FonteHenderson$18K
- Justin GohHenderson$17K
- Sunil KallaHenderson$16K
- Chandrasekhar NaralaHenderson$7K
- Arjun GururajLas Vegas$399K
- Thomas-Duythuc ToReno$339K
- Jay MasonReno$227K
- Joseph StevensonReno$222K
- Devang DesaiReno$206K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.